PLoS Pathogens · 2007 · 92 citations · 44 references
Life SciencesBiotechnologyImmunologyMolecular VirologyNanobiotechnologyVaccinologyNanomedicineNanoparticle-based ImmunotechnologyVaccine Antigen DiscoveryVaccine PlatformsVirus-like NanoparticlesVirus-like Particle VaccinesAb ToxinsAnthrax VaccinesAntitoxin TherapyNanoparticle Vaccine FormulationsNanoparticle Vaccine PlatformsProtective Antigen IdentificationRecombinant Virus-like ParticlesVirus-like Particles
The recent use of Bacillus anthracis as a bioweapon has stimulated the search for novel antitoxins and vaccines that act rapidly and with minimal adverse effects. B. anthracis produces an AB-type toxin composed of the receptor-binding moiety protective antigen (PA) and the enzymatic moieties edema factor and lethal factor. PA is a key target for both antitoxin and vaccine development. We used the icosahedral insect virus Flock House virus as a platform to display 180 copies of the high affinity, PA-binding von Willebrand A domain of the ANTXR2 cellular receptor. The chimeric virus-like particles (VLPs) correctly displayed the receptor von Willebrand A domain on their surface and inhibited lethal toxin action in in vitro and in vivo models of anthrax intoxication. Moreover, VLPs complexed with PA elicited a potent toxin-neutralizing antibody response that protected rats from anthrax lethal toxin challenge after a single immunization without adjuvant. This recombinant VLP platform represents a novel and highly effective, dually-acting reagent for treatment and protection against anthrax.
44
T. Alwyn Jones, Jin-yu Zou, Sandra W. Cowan et al. · Acta Crystallographica Section A Foundations of Crystallography · 1991 · 12.7K citations
Proteolytic Inactivation of MAP-Kinase-Kinase by Anthrax Lethal Factor
Nicholas S. Duesbery, Craig P. Webb, Stephen H. Leppla et al. · Science · 1998 · 1K citations
Identification of the cellular receptor for anthrax toxin
Kenneth A. Bradley, Jeremy Mogridge, Michaël Mourez et al. · Nature · 2001 · 845 citations